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Gene and protein structure and function 
FLNA is a 48-exon gene located at chromosome Xq28 that encodes the 280 kDa 
cytoskeletal protein filamin A (FLNa; UniProt P21333)1,2. The mature FLNa protein of 
2646 amino acids comprises an amino terminal actin-binding domain (ABD) and 24 
immunoglobulin-like domains (IGDs).3,4 The IGDs contribute to rod region 1 (IGDs 1-
15) which facilitates actin binding and rod region 2 (IGDs 16-23) which interacts with 
multiple binding partners. IGD 24 at the carboxyl terminus mediates assembly of 
FLNa monomers into functional homodimers.3 
 
The role of FLNa in megakaryocytes and platelets 
FLNa is widely expressed and interacts with over 90 other proteins, notably 
components of the cytoskeleton, transmembrane receptors and downstream 
signaling mediators (specifically reviewed in platelets in 5). For example, inhibitory 
interactions with FLNa maintain integrin IIb3 in an inactive state, thereby regulating 
normal proplatelet formation from megakaryocytes (MK) and the dynamics of 
activation of mature platelets.6 The FLNa interaction with PACSIN2 regulates 
membrane tubulation in MK and platelets through appropriate localization of 
PACSIN2 to internal membrane systems.7 In platelets, the FLNa-GPIb interaction 
regulates downstream signaling following von Willebrand factor binding and 
contributes to membrane integrity and platelet adhesion in high shear conditions.8,9 
FLNa interactions also support platelet activation responses by enabling the spatial 
localization of Syk to the cytoplasmic membrane and ITAM / ITAM-like containing 
receptors such as GPVI.10  
 
The filaminopathies A 
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Pathogenic variants in FLNA are implicated in several rare human disorders 
collectively referred to as the filaminopathies A.11 The best described of these is 
periventricular nodular heterotopia 1 (PVNH1:OMIM #300049) in which defective 
neuronal migration results in formation of nodular tissue surrounding the cerebral 
ventricles, usually manifesting as epilepsy, sometimes also associated with cardiac, 
connective tissue, gastrointestinal, lung and other abnormalities.12 PVNH1 is an X-
linked dominant disorder in which almost all reported cases are heterozygous 
females. Pre or peri-natal death is common in hemizygous males. Surviving males 
have a severe multisystem developmental disorder or are somatic mosaics for 
pathogenic FLNA variants.12,13 FLNA variants that cause PVNH1 are typically high-
impact and confer loss of FLNa function, or copy number variants, but some are 
missense loss-of-function variants, usually affecting the ABD.14 The filaminopathy A 
termed chronic idiopathic intestinal pseudo-obstruction (CIIP:OMIM #300048) is also 
associated with loss-of-function FLNA variants and may be an alternatively 
expressed form of PVNH1.15  
 
Prevalence of platelet abnormalities in the filaminopathies A 
Amongst the 170 evaluated reports of PVNH1 or CIIP associated with pathogenic 
FLNA variants, thrombocytopenia with or without platelet dysfunction is documented 
in 11 cases from 10 pedigrees with a total of 10 different FLNA variants. These 
include four stop-gain variants, one insertion deletion variant and five copy number 
variants that were incompletely characterized (Figure 1)14-22. There are five reported 
cases in which a normal platelet count is documented13,16-18,23. For the remainder of 
cases, no hematological data are reported. There is a single reported case with a 
missense FLNA variant and thrombocytopenia but without other features of PVNH1, 
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although the pathogenicity of this variant has not been confirmed experimentally.16,24 
Together these observations suggest that thrombocytopenia is an incompletely 
expressed phenotype of PVNH1 and CIIP. Other rare filaminopathies A caused by 
gain-of-function FLNA variants (Table 1) are not associated with thrombocytopenia.  
 
Platelet abnormalities associated with FLNA variants 
In the PVNH1 or CIIP cases with thrombocytopenia, reported symptoms include 
menorrhagia, mucocutaneous hemorrhage, slow wound healing and prolonged 
bleeding times16,18,19,21. In affected cases, the median reported platelet count was 80 
(32-140 x109/L). Thrombocytopenia was associated with enlarged, spherical 
platelets 16,17 with abnormal -granule distribution compared with controls.16 Platelets 
also showed abnormal cytoplasmic distribution of FLNa and reduced total FLNa 
content consistent with diminished total expression of FLNa.16 Other reports have 
demonstrated FLNa expression is absent in a platelet sub-population, likely reflecting 
selective expression of the variant allele only in specific platelets.18,24 MKs from 
patients with loss-of-function FLNA variants have shown defective differentiation and 
structural fragility, with abnormal distribution of FLNa in the cytoplasm16,24. MKs 
generated ex vivo from pluripotent stem cells from filaminopathy A cases showed 
incomplete MK maturation and the production of reduced numbers and enlarged 
platelets and associated with dysregulated RhoA activation.6 
 
In three cases with loss-of-function FLNA variants and a PVNH1-thrombocytopenia  
phenotype, platelets showed reduced aggregation, secretion and glycoprotein VI 
signaling responses to type 1 collagen and to convulxin, and also diminished 
thrombus formation on collagen.16,24 Responses to other activation agonists were 
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similar to controls suggesting a selective defect in GPVI signal transduction, 
consistent with diminished FLNa-Syk localisation to the GPVI complex.24 A patient 
with confirmed Bernard Soulier syndrome harbouring an additional FLNA variant 
(p.V528M) was also found to have abnormal platelet functional responses to 
collagen. Although the authors postulated the FLNA variant directly contributed to 
the abnormal platelet function phenotype25, the pathogenicity of the p.V528M alone 
is questionable because this variant is present in approximately one in 340 alleles in 
unselected populations.26 In another case with features of PVNH1 and CIIP 
associated with an FLNA variant predicting a C-terminal extension of FLNa, platelets 
were normal in number but demonstrated increased aggregation, secretion and 
thrombus formation compared to controls when stimulated with a variety of agonists. 
These changes were attributed to altered interactions between variant FLNa and the 
IIb3 integrin.23  
 
Implications and conclusions 
The heritability of filaminopathy A-associated thrombocytopenia has important 
implications for heterozygous female carriers of FLNA variants, because of the risk 
of a lethal or otherwise severe phenotype in hemizygous male offspring. Appropriate 
preconceptual counselling is essential for women with genotypically proven 
filaminopathy A. However, the possibility of filaminopathy A should also be 
considered in women in which thrombocytopenia may be the only apparent feature 
of filaminopathy A unless central nervous system imaging or other specialist 
investigations are performed. In this circumstance, comprehensive genotyping and 
accurate assessment of the pathogenicity of any observed FLNA variants is 
essential for appropriate counselling of disease risk. Although pathogenicity can 
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confidently be assigned to high impact FLNA variants, currently there is insufficient 
evidence to confidently predict the effects of missense variants without further 
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X-linked dominant periventricular nodular 
heterotopia 
[PVNH1 #300049] 
Abnormal neuronal migration, 
periventricular nodules, seizures, 
congenital cardiac defects 
Yes 
 Chronic idiopathic intestinal pseudo-
obstruction, congenital short bowel 
syndrome 
[CIIP #300048] 
Recurrent symptoms and signs of 
bowel obstruction in the absence of 




Otopalatodigital syndrome 1 
[#311300] 
Cleft palate, skeletal abnormalities, 
deafness 
No 
 Otopalatodigital syndrome 2 
[#304120] 
Skeletal abnormalities, organ 
malformation, frequent prenatal 
death 
No 
 Frontometaphyseal dysplasia  
[#305620] 
Skeletal dysplasia, deafness, 
urogenital defects 
No 
 Melnick-Needles syndrome 
[#309350] 
Severe skeletal dysplasia, prenatal 
and early death in males 
No 
 
Table 1: Disorders associated with pathogenic variants in FLNA (filaminopathies A), divided by reported effects of variant 






Figure 1 Legend 
 
A. Schematic representation of filamin A (UNIPROT 21333) monomer showing the 
actin binding (ABD), calponin-homology (CH1 and CH2) and immunoglobulin-like 
(1-24) domains and hinge regions 1 and 2 (H1 and H2). The amino acid residues 
delimiting the domains are indicated. The arrows below the schematic show the 
amino acid location of stop gain and frameshift FLNA variants (incompletely 
characterised variants not shown). 
B. Previously reported FLNA variants associated with thrombocytopenia. Where 
more than one family member is affected, data is presented for the index case. 
Population estimates allelic frequencies for the missense variants were obtained 
from the GnomAD database https://gnomad.broadinstitute.org/. Age at time of 
report is stated. NR- clinical or platelet phenotype not reported; PVNH1- 
periventricular nodular heterotopia; CIIP- chronic idiopathic intestinal pseudo-
obstruction. UA- unable to ascertain. *The pathogenicity of this variant was not 
confirmed by functional analyses. # “Thrombocytopenia” reported but no platelet 
count stated. 
  
 
 
 
